ArticleFrontiers in genetics2025
A novel end-to-end learning framework for inferring lncRNA-disease associations based on convolution neural network.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transcriptome Dynamics Reveal the Potential Roles of Long Non-Coding RNAs in Regulating Flower Color of Safflowers (International journal of molecular sciences · 2026Article
- Decoding potential lncRNA and disease associations through graph representation learning and gradient boosting with histogram.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In recent years, lots of computational models have been proposed to infer potential lncRNA-disease associations. Methods: In this manuscript, we introduced a novel end-to-end learning framework named CNMCLDA, in which, we first adopted two convolutional neural networks to extract hidden features of diseases and lncRNAs separately. And then, by combining these hidden features of diseases and lncRNAs with known lncRNA-disease associations, we designed five different loss functions. Next, based on errors obtained by these loss functions, we would perform back propagation to fit parameters in CNMCLDA, and complete those missing values in lncRNA-disease relational matrix according to these fitted parameters. In order to demonstrate the prediction performance of CNMCLDA, intensive experiments have been carried out and experimental results show that CNMCLDA can achieve better performances than state-of-the-art competitive predictive models in frameworks of five-fold cross validation, ten-fold cross validation and leave-one-disease-out cross validation respectively. Results and Discussion: Moreover, in case studies of gastric cancer, glioma and breast cancer, there are 19, 17 and 16 out of top 20 candidate lncRNAs inferred by CNMCLDA having been confirmed by recent relevant literatures separately, which demonstrated the outstanding performance of CNMCLDA as well. Hence, it is obvious that CNMCLDA may be an effective tool for prediction of potential lncRNA-disease associations in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.